PSMB9 and nasopharyngeal carcinoma: According to the previous findings, allow CTL precursor frequency to epitopes within LMP1 (an integral membrane protein) in healthy virus carriers; thus, it is likely that the long-term therapeutic benefit in patients with NPC requires the re-formation of both LMP1-specific and LMP2-specific CTL responses [9].